ES2174064T3 - Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas. - Google Patents

Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas.

Info

Publication number
ES2174064T3
ES2174064T3 ES96909150T ES96909150T ES2174064T3 ES 2174064 T3 ES2174064 T3 ES 2174064T3 ES 96909150 T ES96909150 T ES 96909150T ES 96909150 T ES96909150 T ES 96909150T ES 2174064 T3 ES2174064 T3 ES 2174064T3
Authority
ES
Spain
Prior art keywords
sub
sup
optionally replaced
rent
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909150T
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Gaston Stanislas Marcell Diels
Gil Jose Ignacio Andres
Gadea Francisco Javi Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2174064T3 publication Critical patent/ES2174064T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE EL USO DE COMPUESTOS PARA LA FABRICACION DE UN MEDICAMENTO PARA TRATAR ANIMALES DE SANGRE CALIENTE QUE PADECEN ESTADOS DE ENFERMEDAD RELACIONADOS CON UNA ACTIVIDAD ENZIMATICA O CATALITICA ANORMAL DE LA FOSFODIESTERASA IV (PDE IV) Y/O ESTADOS DE ENFERMEDAD RELACIONADOS CON UN EXCESO FISIOLOGICAMENTE PERJUDICIAL DE CITOCINA, EN PARTICULAR ENFERMEDADES ALERGICAS, ATOPICAS E INFLAMATORIAS, POSEYENDO DICHOS COMPUESTOS LA FORMULA (I), LAS FORMAS DE N ALES DE ADICION DE ACIDOS O DE BASES FARMACEUTICAMENTE ACEPTABLES, Y LAS FORMAS ESTEREOQUIMICAMENTE ISOMERAS DE LOS MISMOS, EN LA CUAL R{SUP,1} Y R{SUP,2} SON CADA UNO INDEPENDIENTEMENTE HIDROGENO; ALQUILO C{SUB,1-6}; DIFLUOROMETILO; TRIFLUOROMETILO; CICLOALQUILO C{SUB, 3-6}; UN HETEROCICLO SATURADO DE 5, 6 O 7 ESLABONES QUE CONTIENE UNO O DOS HETEROATOMOS SELECCIONADOS ENTRE OXIGENO, AZUFRE O NITROGENO; INDANILO; BICICLO[2.2.1] LO; ARILSULFONILO; O ALQUILO C{SUB,1-10}SUSTITUIDO; R{SUP,3} ES HIDROGENO, HALO O ALQUILOXIC{SUB,1-6}; R{SUP,4} ES HIDROGENO; HALO; ALQUILO C{SUB,1-6} OPCIONALMENTE SUSTITUIDO; TRIFLUOROMETILO; CICLOALQUILO C{SUB,3-6}; CARBOXILO; ALQUILOXI(C{SUB,1-4})CARBONILO; CICLOALQUIL(C{SUB,36})AMINOCARBONILO; ARILO; HET{SUP,1}; O R{SUP,4} ES UN RADICAL DE FORMULA: FORMAR UN RADICAL BIVALENTE DE FORMULA: {SUB,2} CH{SUB,2} CANDIILO C{SUB,1-4} O ALCANDIILO C{SUB,1-4}; ADICAL BIVALENTE DE FORMULA: R{SUP,9} }OPCIONALMENTE SUSTITUIDO; ALQUIL(C{SUB,1-6})CARBONILO; ALQUILOXI(C{SUB,1-6})CARBONILO; ALQUENILO C{3-6} OPCIONALMENTE SUSTITUIDO; PIPERIDINILO OPCIONALMENTE SUSTITUIDO; ALQUIL(C{1-6})SULFONILO O ARILSULFONILO; ARILO ES FENILO OPCIONALMENTE SUSTITUIDO; HET{SUP,1} ES MORFOLINILO, O UN GRUPO PIRIDINILO, FURANILO, TIENILO, HIDROXIPIRIDINILO, IMIDAZOLILO, TIAZOLILO, OXAZOLILO, ISOQUINOLINILO, QUINOLINONILO, PIPERIDINILO O PIPERAZINILO OPCIONALMENTE SUSTITUIDOS; HET{SUP,2} ES MORFOLINILO, O UN GRUPO PIPERIDINILO, PIPERAZINILO, PIRIDINILO, FURANILO O TIENILO OPCIONALMENTE SUSTITUIDOS. LA PRESENTE INVENCION TAMBIEN TRATA DE NUEVOS COMPUESTOS QUE POSEEN ACTIVIDAD INHIBIDORA DE PDE IV Y DE CITOCINA, DE PROCEDIMIENTOS PARA SU PREPARACION Y DE COMPOSICIONES QUE INCLUYEN DICHOS NUEVOS COMPUESTOS.
ES96909150T 1995-04-06 1996-03-28 Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas. Expired - Lifetime ES2174064T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200868 1995-04-06
EP95202898 1995-10-26

Publications (1)

Publication Number Publication Date
ES2174064T3 true ES2174064T3 (es) 2002-11-01

Family

ID=26139205

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909150T Expired - Lifetime ES2174064T3 (es) 1995-04-06 1996-03-28 Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas.

Country Status (27)

Country Link
US (2) US5994376A (es)
EP (1) EP0819122B1 (es)
JP (1) JP4562101B2 (es)
KR (1) KR100406628B1 (es)
CN (1) CN1068591C (es)
AR (1) AR002732A1 (es)
AT (1) ATE214052T1 (es)
AU (1) AU702947B2 (es)
CA (1) CA2216653C (es)
CY (1) CY2328B1 (es)
CZ (1) CZ293127B6 (es)
DE (1) DE69619661T2 (es)
DK (1) DK0819122T3 (es)
ES (1) ES2174064T3 (es)
HK (1) HK1007880A1 (es)
HR (1) HRP960155A2 (es)
HU (1) HU223324B1 (es)
IL (1) IL117807A (es)
MX (1) MX9707652A (es)
MY (1) MY119254A (es)
NO (1) NO314339B1 (es)
NZ (1) NZ304877A (es)
PL (1) PL187375B1 (es)
PT (1) PT819122E (es)
SI (1) SI0819122T1 (es)
TW (1) TW332201B (es)
WO (1) WO1996031485A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
ATE236884T1 (de) * 1996-10-02 2003-04-15 Janssen Pharmaceutica Nv Pde-iv hemmende 2-cyanoiminoimidazol-derivate
ID24224A (id) * 1997-07-10 2000-07-13 Janssen Pharmaceutica Nv Turunan-turunan 6-azaurasil sebagai inhibitor il-5
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
TR200002801T2 (tr) * 1998-04-01 2000-12-21 Janssen Pharmaceutica N.V. PDE IV engelleyici piridin türevleri
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
JP2002511438A (ja) * 1998-04-14 2002-04-16 スミスクライン・ビーチャム・コーポレイション ホスホジエステラーゼアイソザイム４（ｐｄｅ４）の阻害性化合物
DE69907254T2 (de) 1998-11-23 2004-04-01 Janssen Pharmaceutica N.V. 6-azauracilderivate als il-5 inhibitoren
EA004806B1 (ru) 1998-12-18 2004-08-26 Янссен Фармацевтика Н.В. Производные 6-азаурацила, ингибирующие il-5
EP1322310A4 (en) * 2000-09-13 2004-09-15 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
JP4510383B2 (ja) * 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
US20040146561A1 (en) 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
GB0326407D0 (en) * 2003-11-12 2003-12-17 Glaxo Group Ltd Chemical compounds
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US20080200526A1 (en) * 2004-07-05 2008-08-21 Jin Soo Lee Composition for the Prevention and Treatment of Allergic Inflammatory Disease
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US8354434B2 (en) * 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
WO2008157425A2 (en) * 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
NZ601967A (en) * 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
EP3285760A4 (en) 2015-04-24 2018-09-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL285394A (es) * 1961-11-17
US3184060A (en) 1963-02-13 1965-05-18 Owens Illinois Glass Co Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials
WO1992007567A1 (en) * 1990-11-06 1992-05-14 Smithkline Beecham Corporation Imidazolidinone compounds
ATE234270T1 (de) * 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
TW263495B (es) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
HUP9801575A2 (hu) 1999-01-28
MX9707652A (es) 1997-11-29
US20020068830A1 (en) 2002-06-06
HU223324B1 (hu) 2004-06-28
JPH11503136A (ja) 1999-03-23
CA2216653A1 (en) 1996-10-10
AU5275596A (en) 1996-10-23
WO1996031485A1 (en) 1996-10-10
SI0819122T1 (en) 2002-06-30
EP0819122A1 (en) 1998-01-21
IL117807A (en) 2001-06-14
AR002732A1 (es) 1998-04-29
CN1181072A (zh) 1998-05-06
DE69619661T2 (de) 2002-10-31
HRP960155A2 (en) 1997-10-31
CN1068591C (zh) 2001-07-18
DK0819122T3 (da) 2002-07-01
IL117807A0 (en) 1996-08-04
PL322654A1 (en) 1998-02-16
JP4562101B2 (ja) 2010-10-13
CA2216653C (en) 2009-05-26
US5994376A (en) 1999-11-30
NO974602D0 (no) 1997-10-06
NO314339B1 (no) 2003-03-10
CY2328B1 (en) 2004-02-06
HK1007880A1 (en) 1999-04-30
DE69619661D1 (de) 2002-04-11
CZ293127B6 (cs) 2004-02-18
AU702947B2 (en) 1999-03-11
US6403805B1 (en) 2002-06-11
NZ304877A (en) 1999-06-29
ATE214052T1 (de) 2002-03-15
CZ314997A3 (cs) 1998-12-16
HUP9801575A3 (en) 1999-03-01
NO974602L (no) 1997-10-06
MY119254A (en) 2005-04-30
PT819122E (pt) 2002-08-30
TW332201B (en) 1998-05-21
KR100406628B1 (ko) 2004-05-31
EP0819122B1 (en) 2002-03-06
KR19980703449A (ko) 1998-11-05
PL187375B1 (pl) 2004-06-30

Similar Documents

Publication Publication Date Title
ES2174064T3 (es) Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas.
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
FR2809396B1 (fr) Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2692575B1 (fr) Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
ES2136291T3 (es) Derivados de pirimidina.
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
DE69413118T2 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
ATE67756T1 (de) N-substituierte 3-piperidin- oder 3pyridincarbons|uren und deren derivate.
DK189982A (da) Oligosaccharider med korte kaeder der har biologiske egenskaber deres fremstilling og deres anvendelse som laegemidler
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
ATE3552T1 (de) Verfahren zur herstellung von phosphono-hydroxy- essigsaeure und salzen derselben sowie diese enthaltende autivirale mittel.
PT77238A (de) Substituierte tert.-butanol-derivate verfahren zu ihrer herstellung und diese enthaltende antimykotische mittel
ATE10841T1 (de) Tricyclische thiazolyloxamidsaeuren und derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
DE60111553D1 (de) Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
DK288787A (da) Kondenserede imidazo-heterocycliske forbindelser, fremgangsmaade til deres fremstilling, og deres anvendelse som laegemidler
EP0913396A3 (de) Sulfonamid-substituierte Benzopyranderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
ES2054904T3 (es) Procedimiento para la preparacion de peptidos con actividad inhibidora de sistemas enzimaticos.
ATE18761T1 (de) Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen.
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
ATE140922T1 (de) 3- oder 4-glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches mittel
IT1223395B (it) Composti ad attivita' cardiovascolare
DE3872425D1 (de) Substituierte tetrahydroisochinolin-verbindungen, ihre herstellung und diese enthaltende pharmazeutische mittel.
ES2162022T3 (es) Derivados de tiol con actividad inhibidora de la metalopeptidasa.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
ATE6256T1 (de) N-(4-phenyl-2-thiazolyl)-oxamidsaeure-2ethoxyethylester, verfahren zu seiner herstellung und diesen enthaltende therapeutische mittel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 819122

Country of ref document: ES